IP Library › Granted Patent US 12,576,205
Granted Patent B1
US 12,576,205 · App. 19/315,027 · Granted Mar 17, 2026

Augmented reality visual guidance system for injectable medication administration and verification

Inventor: Jeremy Corbett (Lexington, KY)
Assignee: DataDose, LLC
A61M5/172G16H20/17A61M5/20A61M2205/3553A61M2205/50
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,576,205
App. No.
19/315,027
Granted
Mar 17, 2026
Kind
B1
Abstract

An augmented reality visual guidance system for injectable medication administration combines intelligent injection devices with augmented reality display systems to provide visual guidance for proper injection technique and medication verification. The system includes intelligent injection devices that administer medication and collect administration data including injection completion status, needle positioning data, plunger movement data, or dosage volume measurements, or augmented reality display systems that overlay visual guidance information including injection site targeting, needle insertion angle indicators, depth guidance markers, or real-time technique feedback. The system features visual guidance modules providing real-time instructions, medication verification modules confirming authenticity and dosage accuracy, image recognition systems identifying medication labels and injection sites, real-time feedback systems providing visual indicators, patient interface modules displaying information through smart glasses and mobile devices, or confirmation systems providing visual verification of successful administration. This approach improves injection accuracy and patient safety.

Claims (22)

1 . An augmented reality visual guidance system for smart syringe injection technique and medication verification, comprising:

an intelligent injection device configured to administer medication and collect administration data including one or more of injection completion status, needle positioning data, plunger movement data, or dosage volume measurements;

an augmented reality display system configured to overlay visual guidance information based upon, at least in part, the administration data collected from the intelligent injection device including one or more of injection site targeting, needle insertion angle indicators, depth guidance markers, or real-time technique feedback;

a visual guidance module configured to, based upon, at least in part, the administration data collected from the intelligent injection device:

provide real-time visual instructions for proper injection technique;

display one or more of injection site selection guidance, needle positioning indicators, or administration progress visualization;

adapt visual guidance based on medication type and patient characteristics; and

overlay corrective feedback during injection administration;

a medication verification module configured to verify one or more of medication authenticity, dosage accuracy, expiration status, or proper storage conditions of the intelligent injection device through visual recognition and sensor data analysis;

an image recognition system configured to identify and validate one or more of medication labels, syringe components of the intelligent injection device, injection sites, or patient identification markers;

a real-time feedback system configured to provide visual indicators for one or more of injection technique accuracy, dosage completion status, or administration quality metrics based upon, at least in part, the administration data collected from the intelligent injection device;

a patient interface module configured to display augmented reality information associated with the intelligent injection device through one or more of smart glasses, mobile device displays, or heads-up display systems; and

a confirmation system configured to provide visual verification of successful medication administration using the intelligent injection device through one or more of augmented reality overlays, completion indicators, or digital documentation.

2 . The augmented reality visual guidance system of claim 1 , wherein the visual guidance module is configured to provide step-by-step instructions through one or more of animated overlays, directional indicators, or progress tracking displays.

3 . The augmented reality visual guidance system of claim 1 , wherein the medication verification module is configured to authenticate medications using one or more of barcode scanning, QR code recognition, or pharmaceutical database verification.

4 . The augmented reality visual guidance system of claim 1 , wherein the image recognition system is configured to utilize one or more of computer vision algorithms, machine learning models, or pattern recognition techniques.

5 . The augmented reality visual guidance system of claim 1 , wherein the real-time feedback system is configured to provide visual cues including one or more of color-coded indicators, progress bars, or completion confirmations.

6 . The augmented reality visual guidance system of claim 1 , wherein the patient interface module is configured to adjust display parameters based on one or more of ambient lighting conditions, user preferences, or accessibility requirements.

7 . The augmented reality visual guidance system of claim 1 , wherein the confirmation system is configured to generate documentation including one or more of timestamped records, administration photos, or compliance verification data.

8 . The augmented reality visual guidance system of claim 1 , wherein the visual guidance module is configured to provide personalized instructions based on one or more of patient skill level, previous injection history, or medication-specific requirements.

9 . The augmented reality visual guidance system of claim 1 , wherein the medication verification module is configured to cross-reference medication data with one or more of prescription information, patient medical records, or contraindication databases.

10 . The augmented reality visual guidance system of claim 1 , wherein the augmented reality display system is configured to maintain visual tracking accuracy through one or more of motion sensors, camera positioning, or environmental mapping.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 4, 2025
From: CORBETT, JEREMY
To: DATADOSE, LLC
Reel/Frame 072156/0435 →
Continuity (4)
Continuation In Part 19281005 · Jul 25, 2025
Continuation 19031862 · Jan 18, 2025
Continuation 19030829 · Jan 17, 2025
Provisional Application 63715505 · Nov 1, 2024
References Cited (124)
US 4950246A · Muller · 1990 [cited by applicant]
US 7300418B2 · Zaleski · 2007 [cited by applicant]
US 9317916B1 · Hanina et al. · 2016 [cited by applicant]
US 9623191B2 · Uber et al. · 2017 [cited by applicant]
US 10911515B2 · Biasi et al. · 2021 [cited by applicant]
US 11210611B2 · Kamen et al. · 2021 [cited by applicant]
US 12260959B1 · Minetti et al. · 2025 [cited by applicant]
US 20010047281A1 · Keresman, III et al. · 2001 [cited by applicant]
US 20030036683A1 · Kehr et al. · 2003 [cited by applicant]
US 20030110060A1 · Clementi · 2003 [cited by applicant]
US 20070179453A1 · Lim et al. · 2007 [cited by applicant]
US 20070219503A1 · Loop et al. · 2007 [cited by applicant]
US 20070225653A1 · Lim et al. · 2007 [cited by applicant]
US 20090076338A1 · Zdeblick et al. · 2009 [cited by applicant]
US 20110009812A1 · Brown · 2011 [cited by applicant]
US 20120209243A1 · Yan · 2012 [cited by applicant]
US 20130023813A1 · Roorda · 2013 [cited by applicant]
US 20130023825A1 · Edwards et al. · 2013 [cited by applicant]
US 20130310756A1 · Whalley et al. · 2013 [cited by applicant]
US 20130338628A1 · Robertson et al. · 2013 [cited by applicant]
US 20140074454A1 · Brown et al. · 2014 [cited by applicant]
US 20140180711A1 · Kamen et al. · 2014 [cited by applicant]
US 20140207099A1 · Nagar et al. · 2014 [cited by applicant]
US 20150057611A1 · Bureau · 2015 [cited by examiner]
US 20150112703A1 · Sysko et al. · 2015 [cited by applicant]
US 20150174342A1 · Mitrosky et al. · 2015 [cited by applicant]
US 20150278924A1 · Maurer et al. · 2015 [cited by applicant]
US 20160012205A1 · Saint et al. · 2016 [cited by applicant]
US 20160042154A1 · Goldberg et al. · 2016 [cited by applicant]
US 20160171597A1 · Todeschini · 2016 [cited by examiner]
US 20160171777A1 · Todeschini · 2016 [cited by examiner]
US 20160243318A1 · Despa et al. · 2016 [cited by applicant]
US 20160259913A1 · Yu et al. · 2016 [cited by applicant]
US 20170007765A1 · Cowe et al. · 2017 [cited by applicant]
US 20170076060A1 · Pilkington et al. · 2017 [cited by applicant]
US 20170095638A1 · Young et al. · 2017 [cited by applicant]
US 20170119969A1 · McCullough et al. · 2017 [cited by applicant]
US 20170136185A1 · Rios et al. · 2017 [cited by applicant]
US 20170146381A1 · Eckel et al. · 2017 [cited by applicant]
US 20170245943A1 · Foster et al. · 2017 [cited by applicant]
US 20170262604A1 · Francois · 2017 [cited by applicant]
US 20170325091A1 · Freeman et al. · 2017 [cited by applicant]
US 20180017531A1 · Juhnke et al. · 2018 [cited by applicant]
US 20180085517A1 · Laurence et al. · 2018 [cited by applicant]
US 20180133400A1 · Almoumen · 2018 [cited by applicant]
US 20180182491A1 · Belliveau et al. · 2018 [cited by applicant]
US 20180193564A1 · Dahmani · 2018 [cited by applicant]
US 20180308569A1 · Luellen · 2018 [cited by applicant]
US 20180333543A1 · Diaz et al. · 2018 [cited by applicant]
US 20180369488A1 · Carlsson et al. · 2018 [cited by applicant]
US 20190054247A1 · Dantsker et al. · 2019 [cited by applicant]
US 20190060577A1 · Vallis · 2019 [cited by applicant]
US 20190209777A1 · O'Connell et al. · 2019 [cited by applicant]
US 20190262534A1 · Agard et al. · 2019 [cited by applicant]
US 20190282761A1 · Wilson et al. · 2019 [cited by applicant]
US 20200016331A1 · Lee et al. · 2020 [cited by applicant]
US 20200061301A1 · Hatamian et al. · 2020 [cited by applicant]
US 20200086046A1 · Corbett et al. · 2020 [cited by applicant]
US 20200093993A1 · O'Rourke et al. · 2020 [cited by applicant]
US 20200139053A1 · Faught et al. · 2020 [cited by applicant]
US 20200303047A1 · Bostic et al. · 2020 [cited by applicant]
US 20200390596A1 · Chalberg, Jr. et al. · 2020 [cited by applicant]
US 20210008294A1 · Gentz · 2021 [cited by applicant]
US 20210217516A1 · Nash et al. · 2021 [cited by applicant]
US 20210288950A1 · Rodriguez Bravo et al. · 2021 [cited by applicant]
US 20220023391A1 · Michelich et al. · 2022 [cited by applicant]
US 20220031956A1 · Helmer · 2022 [cited by applicant]
US 20220051778A1 · Kühni et al. · 2022 [cited by applicant]
US 20230191036A1 · Corbett et al. · 2023 [cited by applicant]
US 20230302224A1 · Prince et al. · 2023 [cited by applicant]
US 20230330328A1 · Moberg et al. · 2023 [cited by applicant]
US 20230386677A1 · Ferro et al. · 2023 [cited by applicant]
US 20230414432A1 · Augustine et al. · 2023 [cited by applicant]
US 20230414433A1 · Augustine et al. · 2023 [cited by applicant]
US 20240157045A1 · Kostal et al. · 2024 [cited by applicant]
US 20240232031A1 · Kang et al. · 2024 [cited by applicant]
US 20240285956A1 · Forsell · 2024 [cited by applicant]
US 20250050014A1 · Shin et al. · 2025 [cited by applicant]
US 20250329451A1 · Minetti · 2025 [cited by examiner]
CA 3140408A1 · 2020 [cited by applicant]
EP 3991771A1 · 2022 [cited by applicant]
WO 2006060572A1 · 2006 [cited by applicant]
WO 2016210404A1 · 2016 [cited by applicant]
WO 2017156523A1 · 2017 [cited by applicant]
WO 2018009509A2 · 2018 [cited by applicant]
WO 2018106475A1 · 2018 [cited by applicant]
WO 2020236481A1 · 2020 [cited by applicant]
WO 2021237085A1 · 2021 [cited by applicant]
Non-Final Office Action for U.S. Appl. No. 19/281,013 dated Dec. 11, 2025, 35 pages. [cited by applicant]
Non-Final Office Action for U.S. Appl. No. 19/281,035 dated Dec. 11, 2025, 29 pages. [cited by applicant]
International Search Report and Written Opinion for PCT Application No. PCT/US2021/033646 dated Oct. 20, 2021, 14 pages. [cited by applicant]
Extended European Search Report dated May 23, 2024 for European Application No. 21808546.2, 8 pages. [cited by applicant]
Non-Final Office Action for U.S. Appl. No. 16/131,749, dated Apr. 1, 2020, 9 pages. [cited by applicant]
Final Office Action for U.S. Appl. No. 16/131,749, dated Oct. 1, 2020, 11 pages. [cited by applicant]
Non-Final Office Action for U.S. Appl. No. 16/131,749, dated Mar. 2, 2021, 13 pages. [cited by applicant]
Non-Final Office Action for U.S. Appl. No. 16/131,749, dated Sep. 16, 2021, 10 pages. [cited by applicant]
Notice of Allowance for U.S. Appl. No. 16/131,749, dated Jan. 13, 2022, 7 pages. [cited by applicant]
Non-Final Office Action for U.S. Appl. No. 17/724,177, dated Apr. 11, 2024, 11 pages. [cited by applicant]
Final Office Action for U.S. Appl. No. 17/724,177, dated Oct. 22, 2024, 13 pages. [cited by applicant]
Non-Final Office Action for U.S. Appl. No. 17/724,177 dated Apr. 21, 2025, 9 pages. [cited by applicant]
Restriction Requirement Office Action for U.S. Appl. No. 19/031,780 dated May 19, 2025, 6 pages. [cited by applicant]
Non-Final Office Action for U.S. Appl. No. 19/031,780 dated Aug. 6, 2025, 30 pages. [cited by applicant]
Restriction Requirement Office Action for U.S. Appl. No. 19/031,836 dated Apr. 25, 2025, 6 pages. [cited by applicant]
Non-Final Office Action for U.S. Appl. No. 19/031,836 dated Jul. 18, 2025, 17 pages. [cited by applicant]
Restriction Requirement Office Action for U.S. Appl. No. 19/031,854 dated May 9, 2025, 6 pages. [cited by applicant]
Notice of Allowance for U.S. Appl. No. 19/031,854 dated Jul. 28, 2025, 32 pages. [cited by applicant]
Restriction Requirement Office Action for U.S. Appl. No. 19/031,862 dated May 9, 2025, 6 pages. [cited by applicant]
Notice of Allowance for U.S. Appl. No. 19/031,862 dated Jul. 29, 2025, 43 pages. [cited by applicant]
Non-Final Office Action for U.S. Appl. No. 19/031,940 dated Apr. 11, 2025, 25 pages. [cited by applicant]
Final Office Action for U.S. Appl. No. 19/031,940 dated Jul. 3, 2025, 13 pages. [cited by applicant]
Restriction Requirement Office Action for U.S. Appl. No. 17/926,157 dated Sep. 24, 2025, 6 pages. [cited by applicant]
Notice of Allowance for U.S. Appl. No. 19/031,940 dated Oct. 17, 2025, 21 pages. [cited by applicant]
Final Office Action for U.S. Appl. No. 17/724,177, dated Oct. 29, 2025, 32 pages. [cited by applicant]
Examination Report dated Nov. 17, 2025 for European Application No. 21808546.2, 5 pages. [cited by applicant]
Final Office Action for U.S. Appl. No. 19/031,836 dated Nov. 26, 2025, 26 pages. [cited by applicant]
Non-Final Office Action for U.S. Appl. No. 19/280,969 dated Dec. 1, 2025, 38 pages. [cited by applicant]
Notice of Allowance for U.S. Appl. No. 19/031,780 dated Dec. 29, 2025, 20 pages. [cited by applicant]
Non-Final Office Action or U.S. Appl. No. 19/314,966 dated Dec. 31, 2025, 42 pages. [cited by applicant]
Notice of Allowance for U.S. Appl. No. 19/315,011 dated Jan. 7, 2026, 39 pages. [cited by applicant]
Notice of Allowance for U.S. Appl. No. 19/314,936 dated Jan. 13, 2026, 30 pages. [cited by applicant]
Notice of Allowance for U.S. Appl. No. 17/724,177 dated Jan. 13, 2026, 12 pages. [cited by applicant]
Notice of Allowance for U.S. Appl. No. 19/031,881 dated Jan. 14, 2026, 49 pages. [cited by applicant]
Non-Final Office Action for U.S. Appl. No. 17/926,157 dated Jan. 21, 2026, 53 pages. [cited by applicant]
Mahzabin, Rahnuma et al. “Blockchain associated machine learning and IoT based hypoglycemia detection system with auto-injection feature”, Indonesian Journal of Electrical Engineering and Computer Science, vol. 27, No. … [cited by applicant]